Stay updated on COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Sign up to get notified when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.

Latest updates to the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check14 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check57 days agoChange DetectedThe web page has been updated to version 2.15.0, replacing the previous version 2.14.4.SummaryDifference1.0%
- Check64 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check107 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
Stay in the know with updates to COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Enter your email address, and we'll notify you when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.